About
Antibody-Cell Conjugation Therapy
Areas of Focus
Categories
Stem Cell & Cellular TherapyBiotech
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
0
As Collaborator
3
Total Enrollment
96
By Phase
PHASE2/PHASE3: 1PHASE1: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 2WITHDRAWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
Today
Hover over trial bars to see details
Recent Trials
NCT03165435Collaborator
A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
PHASE2/PHASE3Withdrawn
Started: Jul 31, 2018 · Completed: Dec 31, 2019
NCT03594890Collaborator
Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects
PHASE1Completed
72 participants
Started: Jun 12, 2018 · Completed: Aug 7, 2019
NCT02609022Collaborator
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
PHASE1/PHASE2Completed
24 participants
Started: Mar 31, 2016 · Completed: Sep 30, 2018
Locations (1)
Headquarters
Alameda, CA, United States
Map
Loading map...